top of page

PROF.  PRABHAS  MOGHE

Effective October 2020, Dr. Moghe was appointed as Executive Vice President for Academic Affairs (EVPAA) for Rutgers, the State University of New Jersey, the second ranking administrative role at Rutgers, reporting to the President.  Previously, Dr. Moghe served as Provost and Executive Vice Chancellor for Research & Academic Affairs and the inaugural Vice Chancellor for Research & Innovation at Rutgers University-New Brunswick campus.
 
Dr. Moghe has been a scientist, educator, and entrepreneur-scholar at Rutgers.  In recognition of his scholarship and research leadership, Professor Moghe was promoted to a Distinguished Professorship at Rutgers in 2013.  From 2014-2018, Professor Moghe was appointed as the first Research Director for the Rutgers School of Engineering’s Alliances and Partnerships with Biomedical and Health Sciences.  Dr. Moghe has advised over 25 PhD students to date, and secured funding over $15M, resulting in over 100 peer-reviewed journal publications, >250 conference presentations and >100 invited seminars.  
 
The Moghe lab recently showcased the ability of short wave infrared emitting nanoprobes to discern multi organ cancer metastases (Nature Biomedical Engineering, 2017).  The Moghe team has advanced a new class of polymer nanotherapeutics for treatment of cardiovascular disease (PNAS, 2015).  Additional innovations from the Moghe lab include the design of innovative shortwave infrared imaging probes for deeper tissue imaging of micrometastatic lesions (Nature Communications 2013), a new concept of high content imaging informatics of stem cell phenotypes (PNAS, 2010; Scientific Reports, 2017), and an advance in the reprogramming and brain-transplantation of human induced neurons within 3D devices from induced pluripotent stem cells (Nature Communications 2016; selected by the NIH-NIBIB as one of its scientific highlights for 2016). 

Selected Research Advances from the Moghe Lab

The Moghe lab successfully transplanted 3-D prenetworked reprogrammed human neurons in vivo (Nature Commun. 2016).  Collaborators include Drs. Pang, Kohn, Hart, from Rutgers and Wernig (Stanford).

Dr. Moghe has pioneered the design of "Nanolipoblockers", co-invented with Dr. Uhrich (PNAS, 2015; Lipotherix).  The NLBs are a new class of nanotherapeutics for cardiovascular disease.  The NLB team pictured above in 2015.  See link below for more details.

bottom of page